New digital platform aims to catch Alzheimer's before symptoms worsen
NCT ID NCT07272811
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a digital platform that uses EEG, eye-tracking, and blood flow sensors to detect early signs of Alzheimer's in people with mild cognitive impairment. Researchers will follow 100 participants aged 55–80 for 12 months to find markers that predict progression to dementia. The goal is to create a non-invasive tool for earlier diagnosis and targeted care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple, non-invasive tool for catching Alzheimer's early, when interventions might work better.
- What could go wrong
- This is an early-stage observational study with only 100 participants. The platform may not prove accurate enough for widespread use, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS San Raffele
RECRUITINGMilan, Italy, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Could your heart hold the key to Alzheimer's prevention?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a Voice-Based app map healthy brain aging across 80 years?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can brain scans and gut bacteria reveal Alzheimer's secrets?